$398 Million is the total value of DAFNA Capital Management LLC's 87 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | PARDES BIOSCIENCES INC | $3,822,000 | – | 233,500 | +100.0% | 0.96% | – | |
| AXGN | New | AXOGEN INC | $3,112,000 | – | 332,103 | +100.0% | 0.78% | – |
| BMEA | New | BIOMEA FUSION INC | $2,339,000 | – | 313,923 | +100.0% | 0.59% | – |
| RGLS | New | REGULUS THERAPEUTICS INC | $1,750,000 | – | 5,555,555 | +100.0% | 0.44% | – |
| SURF | New | SURFACE ONCOLOGY INC | $1,506,000 | – | 315,000 | +100.0% | 0.38% | – |
| ASND | New | ASCENDIS PHARMA A/Ssponsored adr | $1,480,000 | – | 11,000 | +100.0% | 0.37% | – |
| New | THESEUS PHARMACEUTICALS INC | $1,236,000 | – | 97,500 | +100.0% | 0.31% | – | |
| WVE | New | WAVE LIFE SCIENCES LTD | $1,225,000 | – | 390,161 | +100.0% | 0.31% | – |
| BDTX | New | BLACK DIAMOND THERAPEUTICS I | $1,099,000 | – | 206,100 | +100.0% | 0.28% | – |
| SCYX | New | SCYNEXIS INC | $740,000 | – | 121,242 | +100.0% | 0.19% | – |
| CMPX | New | COMPASS THERAPEUTICS INC | $622,000 | – | 196,091 | +100.0% | 0.16% | – |
| ADAP | New | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $511,000 | – | 136,266 | +100.0% | 0.13% | – |
| LCTX | New | LINEAGE CELL THERAPEUTICS IN | $196,000 | – | 80,000 | +100.0% | 0.05% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.